Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases (Q34582536)

3 August 2017

title

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases (English)

1 reference

3 August 2017

6

Steven A Rosenberg

1 reference

3 August 2017

Lisa M Guirguis

1

1 reference

3 August 2017

James C Yang

2

1 reference

3 August 2017

Donald E White

3

1 reference

3 August 2017

Seth M Steinberg

4

1 reference

3 August 2017

David J Liewehr

5

1 reference

3 August 2017

Douglas J Schwartzentruber

7

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

published in

Journal of Immunotherapy

1 reference

3 August 2017

volume

25

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

82-87

1 reference

Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424228

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424228

Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424228

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424228

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

27 October 2018

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

12 December 2020

Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma

1 reference

12 December 2020

Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer

1 reference

12 December 2020

10.1097/00002371-200201000-00009

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference